Brain laterality in schizophrenia has been examined through the application of functional neuroimaging methods. These methods have included the 133 Xenon technique for measuring cerebral blood flow (CBF); positron emission tomography for assessing rates of glucose metabolism, CBF, and neuroreceptor functionbig; single photon emission computerized tomography for studying CBF and neuroreceptors; and functional magnetic resonance imaging for measuring changes attributable to CBF. This article highlights the application of this technology in schizophrenia research, emphasizing more recent studies that have evaluated hemispheric differences. There is evidence for lateralized abnormalities in some studies that have examined this dimension. In general, the results implicate abnormalities in left hemispheric activity. Recent advances in basic and clinical neuroscience provide an opportunity for focused application of functional Imaging in neurobiological studies of schizophrenia.
The application of functional brain imaging methods to the study of schizophrenia has provided an opportunity to test hypotheses generated by human and animal studies, as reviewed in this issue of the Schizophrenia Bulletin. These methods, developed in the past two decades, include the 133 Xenon technique for measuring cerebral blood flow (CBF); positron emission tomography (PET) for assessing cerebral metabolism, CBF, and neuroreceptor functioning; single photon emission computerized tomography (SPECT) for studying CBF and neuroreceptors; and, more recently, functional magnetic resonance imaging (fMRI) for measuring changes attributable to CBF. This article will review the application of this technology in schizophrenia research emphasizing laterality.
While the focus is laterality, it is important to examine these studies in the context of other findings and to integrate the research with our current understanding of brain function in schizophrenia.
Links between clinical features of schizophrenia and brain function have been guided by hypotheses relating behavior to brain regions and systems that have been implicated in schizophrenia. These links are based on preclinical research (Cowell et al. 1999 , this issue) and the emergence of symptoms commonly seen in schizophrenia that also occur following brain lesions. Persistent negative symptoms were initially related to frontal lobe dysfunction, because similar behaviors are evident as sequelae of frontal lobe damage. These sequelae include impairment in abstraction, verbal fluency, mental flexibility, and concept formation. Positive, productive symptoms of hallucinations and delusions have been related to the temporolimbic system. This link has been further strengthened by correspondence of behavior seen in schizophrenia and that observed in patients with temporal lobe epilepsy (Flor-Henry 1976) and more recently with evidence of impaired learning and memory (Saykin et al. 1991) . Crow (1990) has suggested that temporal lobe asymmetry is pivotal to the etiology of schizophrenia. Subcortical regions, with special emphasis on the basal ganglia, have been examined initially in the context of the dopamine hypodiesis and later with respect to other neurotransmitters (Carlsson and Carlsson 1990) .
Laterality measures, reflecting the relation between left and right hemispheric parameters, have been compared in patients with schizophrenia and healthy controls across these brain systems. This has been done for global left and right hemisphere metabolism and CBF, as well as for regional values where specific regions implicated in the pathophysiology of schizophrenia have been examined. Earlier studies have evaluated physiological meas-ures at rest, or baseline. A methodological difficulty in evaluating this research as it relates to the laterality hypothesis is that many of these studies consider lateralized abnormalities to be present (or absent) based on whether effects were significant for one hemisphere. This method does not provide information on whether the differences between the hemispheres are significant
To test the laterality hypothesis it is necessary to define a specific index that subtracts activity in one hemisphere from activity in the other while correcting for individual differences in global absolute values (e.g., left minus right divided by their mean or corrected for global values by regression). The hypothesis is supported if this index differs from zero. Alternatively, the laterality dimension can be examined with methods such as multivariate analysis of variance using hemisphere as a repeated-measures factor. Without such procedures it is difficult to gauge lateralized abnormalities. The application of neurobehavioral probes, in which brain activity is examined during performance of cognitive tasks (Gur et al. 1992) , has further enhanced our ability to evaluate brain systems that regulate cognitive processes in healthy people and dysfunction in people affected by schizophrenia.
Thus, major technological developments with increased resolution and image processing capabilities have moved the field from two-dimensional methods that yield a limited number of physiologic parameters ( 133 Xenon clearance) to three-dimensional studies that provide a wide range of measures (PET, SPECT, MRI). Advances in neuroscience have generated more refined hypotheses that can be tested using functional neuroimaging. These tools permit in vivo examination of humans involving both resting and activated functional measures and may play an increasingly important role in translational research integrating basic and clinical neuroscience.
Laterality in Metabolism and Blood Flow Studies
Metabolism and CBF in schizophrenia have been measured across a number of methods, at a resting state as well as during challenges, in the form of neurobehavioral tasks or pharmacologic interventions. Comparisons have been made between patients with schizophrenia and healthy controls. Within patients, symptom dimensions and severity have been related to brain activity. This literature, which has been reviewed (Buchsbaum 1990; Gur and Pearlson 1993; Kotrla and Weinberger 1995) , also examined other gradients such as anterior-posterior and cortical-subcortical, in addition to laterality. Several cortical and subcortical regions have been implicated, suggesting abnormalities in the frontal lobes (Weinberger et al. 1986; Wolkin et al. 1988; Andreasen et al. 1992; Buchsbaum et al. 1992) , temporolimbic structures (DeLisi et al. 1989; Rubin et al. 1991; Tamminga et al. 1992) , and basal ganglia (Buchsbaum et al. 1987; Resnick et al. 1988; Biver et al. 1995) . Differences between patients and controls have been reported in region compared with whole-brain activity and in the pattern of lateralized activity. As highlighted in a previous issue of the Schizophrenia Bulletin (Buchsbaum 1990 ), the laterality dimension interacts with cortical and subcortical brain structures in anterior and more posterior brain regions. Because this work has been reviewed and is extensive, here we will limit discussion to studies that illustrate laterality findings and their integration with clinical and neurobehavioral measures. This will be followed by a more detailed examination of research published more recently .
Resting blood flow and metabolic studies can contribute to understanding the pathophysiology of schizophrenia when these measures are obtained in a standardized setting with controlled sensory and motor conditions. Such procedures provide reliable quantitative parameters of brain activity that can be related to clinical, neurobehavioral, and neuroanatomic variables. Earlier studies comparing resting values between patients and controls have noted differences in laterality indices, suggesting relatively higher left compared to right hemispheric values in patients, an effect that was pronounced in patients with more severe symptoms (Sheppard et al. 1983; Gur et al. 1989) . Furthermore, improvement in clinical status correlated with a shift toward lower left hemispheric relative to right hemispheric metabolism (Gur et al. 1987a . PET studies of temporal lobe metabolism include findings of increases in both (e.g., DeLisi et al. 1989; Gur et al. 1995) and decreases in glucose utilization. Decreased metabolism was also noted in hippocampus and anterior cingulate cortex (Tamminga et al. 1992) . Metabolism and flow pattern in temporolimbic regions have also been related to symptoms. Liddle et al. (1992) used 15 Oxygenlabeled water with PET and described abnormal CBF in parahippocampal gyms associated with positive symptoms, and Musalek et al. (1989) found hallucinations to be associated with SPECT flow changes in hippocampus, parahippocampus, and amygdala. There are conflicting reports of superior temporal gyms functional changes in schizophrenia during active auditory hallucinations. Cleghorn (1990) suggested that patients with hallucinations have significantly lower relative metabolism in Wemicke's region. Anderson et al. (1991) showed asymmetric temporal lobe perfusion, lower on the left than the right, in schizophrenia patients with auditory hallucinations. DeLisi et al. (1989) found greater metabolic activity in the left anterior temporal lobe that was related to the severity of symptoms. This finding is consistent with Gur et al. (1987i>, 1989 reports of an association between severity of symptoms and relative increase in left hemispheric metabolism measured with PET. Functional changes in the basal ganglia have also been examined with PET and SPECT. Several PET studies implicate basal ganglia dysfunction in schizophrenia (Buchsbaum et al. 1987; Gur et al. 1987a, 19876) . Neuroleptic-naive patients were reported to have relatively increased blood flow in left globus pallidus (Early et al. 1989 ).
The pharmacologic status of patients undergoing metabolic and blood flow studies varies. Research ranges from investigations in which neuroleptics were noted but not controlled, to studies conducted after a period of washout, to those where pharmacologic intervention was introduced in a standardized fashion to examine treatment effects on regional metabolic landscape. The washout period in studies that attempted to control for the effects of neuroleptics on CBF and metabolism commonly has been short, ranging from 2 to 4 weeks, a compromise with what is clinically feasible and desirable. Siegel et al. (1993) examined glucose activity in cortical-striatalthalamic circuits in a large sample of unmedicated men with schizophrenia and found low metabolic activity in medial frontal cortical regions and the basal ganglia, as well as impaired lateralization patterns in frontal and temporal regions.
A recent strategy applied in schizophrenia research that is important in functional neuroimaging is the study of neuroleptic-naive first-episode patients. This population is particularly informative when the focus of the study is the effect of pharmacologic intervention; studying neuroleptic-naive patients before pharmacologic intervention permits evaluation of the disease state separate from its treatment. A pattern of abnormalities is evident in first-episode patients across studies (e.g., Gur et al. 1995; Vita et al. 1995; Buchsbaum et al. 19%; Andreasen et al. 1997) , indicating that disruption in normal brain processes exists already at presentation and cannot be attributed to treatment or chronicity. Few PET studies have comprehensive clinical data obtained in prospective samples that include neuroleptic-naive first-episode patients followed longitudinally. Most studies have small samples of chronic patients, are cross-sectional, and have applied a single clinical scale or typology. Given the heterogeneity of schizophrenia, its understanding as a brain disorder requires large, well characterized samples where psychopathology is assessed along multiple dimensions. Ultimately, the metabolic data need to be integrated with other parameters of brain structure and function.
We reported a PET study with fluorodeoxyglucose, cross-registered with MRI, in 42 patients with schizophrenia and 42 controls in which 22 patients were neuroleptic-naive and 20 had been previously treated but were off medications. There were no differences between groups in whole-brain metabolism or regional ratios, nor in anterior-posterior gradients, but the laterality index (left minus right) was higher in patients for the midtemporal region, reflecting relatively higher metabolism in the left compared to the right hemisphere. Data on all standard regions that can be reliably measured are presented in figure 1. As can be seen, the metabolic rates averaged across hemispheres are remarkably the same for the healthy controls and both groups of patients. Likewise, the laterality index (percent left minus right divided by the average) is similar in all regions except for the midtemporal area, where both patient groups had higher laterality, reflecting relatively greater left than right hemispheric activity. This higher laterality was pronounced in patients with negative and psychotic Schneiderian (Schneider 1959) symptoms and absent in the paranoid group. Furthermore, patients with more severe memory impairment had higher laterality scores than their counterparts with less impairment (Mozley et al. 1996 ). Higher metabolic rates and lower relative left hemispheric values were associated with better premorbid adjustment and outcome. A higher subcortical-cortical gradient was noted in first-episode patients. We concluded that there were no resting abnormalities in absolute metabolic rates in any brain region, but abnormal gradients are evident. These vary in subtypes, and laterality is associated with functioning. The results support the hypothesis of temporolimbic disturbance in schizophrenia that is already present at the onset of illness.
An overview of functional imaging studies in schizophrenia published during 1996-97 is presented in table 1. Pertinent information related to sample characteristics is also included. Sample sizes ranged from 8 to 79 patients and 6 to 47 healthy controls, with the majority of studies having fewer than 20 subjects per group. The preponderance of male participants precludes evaluation of sex differences, an important moderating variable in the study of brain function and in schizophrenia. Most participants were in their second or third decade of life. Regarding medication status at the time of scanning, four studies included neuroleptic-naive patients only, and the rest evaluated a mixture of treated patients who were clinically stable, chronic patients off neuroleptics, and few neuroleptic-naive patients. It is not clear whether there is an overlap in samples reporting from the same laboratory.
These studies applied diverse methodologies. Studies involving resting measure of CBF with PET [
15 O] , PET [ n C]fluorodeoxyglucose (Bertollo et al. 1996) , and SPECT 99m Tc-hexamethylpropyleneamine oxime (Kawasaki et al. 1996; Klemm et al. 1996a; Miller et al. 1997; Sabri et al. 1997) have ; MB = Mammillary Body; TH = Thalamus; Ml •= Midbrain; PO -Pons; CE = Cerebellum. Lobes: Cortical regions are grouped by lobe in a rostral-caudal order, followed by corpus callosum and subcortical regions. This order heuristically reflects also ontogenic and evolutionary development. Top graph: means+standard error of mean of region to whole brain (R/WB) ratios; bottom graph: laterality differences in percentage, that is, 100*(L-R)/mean(L,R). CMRglu -cerebral metabolic rate for glucose.
reported laterality effects with greater involvement of the left hemisphere, suggesting reduced activity in multiple regions including frontal, temporal, parietal, and basal ganglia. A variety of neurobehavioral tasks were administered during scanning in studies that examined CBF and metabolism. These have probed attention, language, and memory. The majority of studies reported left hemispheric abnormalities, some bilateral abnormalities, and a few primarily right hemispheric effects. In most of the activation studies there is hypoperfusion relative to healthy participants. Only a small number of studies have directly tested laterality gradients, which makes our overall conclusions very tentative.
One observation that seems to show some consistency is that the temporal lobe of patients is relatively more active, while neuroanatomic studies of cortical regions, some performed on the same samples, suggest decreased volume in the left temporal lobe (see Petty 1999, this issue) . Metabolic measures are obtained per unit volume of tissue, suggesting overactivation in the same temporal regions that are anatomically compromised. As an indirect test of the hypothesis, we examined the correlations between frontal and temporal metabolic rates and the cerebral spinal fluid (CSF) volumes in these regions. As shown in figure 2, healthy people showed no correlations between CSF volume and metabolism and positive correlations between brain tissue volume and Neurobehavioral tasks during imaging: CPT = continuous performance test; AST = anti-saccade task; VF = verbal fluency task; WLG = word list generation task; AV = auditory-verbal task; SSM = supraspan memory task; AUD = auditory stimuli; WCS = Wisconsin Card Sorting; NM = number matching.
3 Subjects: C -control subjects; S -schizophrenia subjects. 
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metabolism. People with schizophrenia, conversely, showed significant positive correlations between CSF volume and metabolic activity for the temporal lobe regions; only small correlations were obtained between brain tissue volume and metabolism in the frontal lobes. This finding suggests that the degree of metabolism is higher in patients with atrophy-related changes. The hypothesis can be tested more directly and, if supported, could point to both pharmacologic and neurocognitive rehabilitation strategies. The introduction of fMRI is an exciting development in functional imaging research. fMRI offers several advantages over other methods, such as PET, for imaging brain function: higher spatial resolution, higher temporal resolution, noninvasiveness and lack of ionizing radiation, direct correlation with anatomical imaging, greater repeatability, and economy. Disadvantages of fMRI include the presence of loud background noise generated by the gradients, difficulties in presenting stimuli and performing tasks in the magnet bore, claustrophobia, low signal-to-noise ratios for most methods, and lack of quantitation in physiologic units. The use of specialized equipment compatible with the MRI environment can overcome most of these disadvantages. Among the various fMRI methods, blood oxygenarion level dependent (BOLD) imaging has been most widely applied (Bandettini et al. 1992; Kwong et al. 1992) . This technique relies on magnetic susceptibility effects of deoxyhemoglobin, which cause regional signal decreases in imaging sequences sensitive to susceptibility (e.g., echoplanar). With regional brain activation studies, a net increase in signal intensity is observed in regions known to be activated by the task. This increase in image intensity corresponds to a local decrease in deoxyhemoglobin attributed to an increase in regional blood flow compared to regional oxygen consumption. A typical response is a 1 to 25 percent increase in regional image intensity, which develops over 3 to 8 seconds following task initiation. The method is radiation free and more easily amenable to repeated measures.
We are still early in the application of this technology in the study of schizophrenia. Renshaw et al. (1994) measured the relative magnitude of the change in image signal intensity caused by photic stimulation, in eight patients and nine controls. The mean signal intensity change in the primary visual cortex was significantly greater in patients than in controls. Sensorimotor cortex and supplementary motor area (SMA) activation were examined in right-handed patients and controls during finger-to-thumb opposition. All subjects showed activation of the SMA and both ipsilateral and contralateral sensorimotor cortices. Compared with controls, patients showed a decreased activation of both sensorimotor cortices and SMA, as well as a reversed lateralization effect (Wenz et al. 1994) . Yurgelun-Todd et al. (1996) examined 12 patients with schizophrenia and 11 controls during a word fluency task. Patients showed less left frontal activation and greater left temporal activation than controls. With increased understanding of the technology and elucidation of neural systems processing tasks in healthy people, our ability to apply fMRI to schizophrenia will also be enhanced.
Neuropharmacologic Studies
A second area of valuable research in the integration of neuropharmacology and functional imaging involves combining controlled therapeutic interventions with functional imaging studies that measure cerebral metabolism or blood flow. The topography of brain activity can be evaluated at "baseline," before pharmacologic intervention, and repeated after a period of treatment. The pattern of change in brain activity can be related to changes in clinical status. Table 1 highlighted the medication status of participants in the studies listed; however, most studies of CBF and metabolism have not applied a rigorous design to examine the effects of standardized pharmacologic interventions in large samples (see reviews in Gur 1995 and Miller etal. 1997) .
The study of neuroreceptors provides the most direct examination of neuropharmacologic aberrations. These open a window for assessing the nature of neurochemical abnormalities in schizophrenia. Advances in elucidating the pathophysiology of schizophrenia require an understanding of neurotransmitter function. Accordingly, the application of PET and SPECT to the study of receptor occupancy is an important research domain. These efforts have been guided both by an extensive psychopharmacologic literature and by advances in basic neuroscience on neuroreceptor subtyping and postmortem research. Functional neuroimaging is the meeting ground for preclinical and clinical neuropharmacology. Human neuroreceptor PET studies have built on progress with in vitro binding measurements of receptor density and affinity and neuroreceptor autoradiography (Sedvall et al. 1986; Wong et al. 1986) , and these studies have been summarized (Sedvall 1992; Gur and Pearlson 1993; Gur 1995) . Most of these studies have not specifically evaluated laterality.
An overview of recent functional imaging neuropharmacologic studies is presented in table 2.
The PET ligand [ n C] raclopride has been applied in earlier studies (Farde et al. 1988 (Farde et al. , 1990 Farde 1992) , as well as in a number of more recent studies summarized in table 2. Sample size ranged from 4 to 12 patients, and most studies did not include a healthy comparison sample. Medication status ranged from neuroleptic-naive to being off neuroleptics for 2 to 3 weeks or being actively treated. The PET ligand [ u C]-N-methyl spiperone ([ n C]-NMSP) has also been examined in two recent studies. In one study, Goyer et al. (1996) evaluated the occupancy of serotonin (5-HT 2A ) and dopamine D 2 receptors in five untreated subjects (two healthy controls, two patients with schizophrenia, and one patient with bipolar illness), five patients treated with typical neuroleptics, and five treated with clozapine. The 5-HT 2A index separated subjects treated with clozapine from participants in the two other groups, whereas the D 2 index separated subjects treated with typical neuroleptics from all other participants. In the second study, Wong and colleagues pursued their earlier work (Wong et al. 1986 ) with [ n C]-NMSP in a larger study of neuroreceptor imaging (Wong et al. 1997 ). All patients with schizophrenia (10 from the previous sample and 12 new patients) were neuroleptic-naive. The sample of bipolar patients, both with and without psychotic features, enabled Wong and colleagues to address the issue of specificity and the underlying mechanism of psychosis. They noted a decline in dopamine receptors associated with aging across all subject groups. Psychosis, across disorders, was associated with B max elevation of D 2 -like receptors. As can be seen from this review, most studies have not examined laterality effects or reported abnormalities bilaterally. Of note is that post-mortem studies, shown at the bottom of table 2, tend to report lateralized abnormalities to the left hemisphere.
Conclusions
Functional neuroimaging research in schizophrenia has made progress in two areas: regional brain energy metabolism and blood flow and neuroreceptor studies. Such studies can play an important role in neurobiologic research in schizophrenia by advancing the understanding of brain dysfunction related to neurobehavior and neuropharmacology. The field has reached some maturity in developing appropriate paradigms. There is now a need for adequate sample size in patient and healthy populations, with attention to clinical heterogeneity and variability in brain function in relation to gender and age.
Two complementary types of probes can enhance our understanding of brain function in schizophrenia. The 32±3  29±3  30±4  34±6  30±5  33±10  26±9  25±5  29±11  38±6  33±6  33±6  27±6  29±7  34±16  32±9  51 ±17  42±2 Subjects: C = control subjects; S = schizophrenia subjects; B » bipolar subjects; Cm= medicated control subjects; Sc -completed suicide; AD PD -Parkinson's disease subjects; HD = Huntingdon's disease subjects.
3 Age: Ages have been rounded off to the nearest whole number; NA = not available.
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Region abbreviations: L -left; R = right; ST -striatum; PFC » prefrontal cortex; P/OC = parietal-occipital cortex; TL -temporal lobe; LS -limblc system; PT = putamen; BG = basal ganglia; FL »frontal lobe; NC » neocortex; ACG = anterior dngulate gyrus; TH = thalamus; CB -cerebellum; MFL » medial frontal lobe; F/TC -frontal-temporal cortex; T/PC = temporal-parietal cortex; OMPFC = orbitomedial prefrontal cortex; DLPFC -dorsolateral prefrontal cortex; MTL = mesial temporal lobe; CD -caudate; HC = hippocampus; IN -insula; SN -substantia nlgra; EC -entortiinal cortex; OFL -orbitofrontal lobe.
by guest on May 2, 2016 http://schizophreniabulletin.oxfordjournals.org/ Downloaded from first is the study of neuroreceptors as described by Sedvall (1992) . Second are neurobehavioral probes (Gur et al. 1992) , which provide a useful paradigm for perfusion studies. Some functional imaging studies have examined laterality. There seems to be greater evidence for left hemispheric dysfunction at baseline studies, whereas paradigms that have introduced neurobehavioral probes as an activation procedure are more probe dependent.
The challenge in this research is to integrate neuroimaging with basic, neurobehavioral, and clinical variables. A potential strength of functional neuroimaging is the integration of neuroreceptor and perfusion studies. Ultimately, dysfunctional neurotransmitter systems translate to aberrant perfusion. Because CBF and metabolism reflect neuronal activity, relating these domains is prerequisite to understanding the neurobiology of schizophrenia. As new receptor subtypes are cloned and radioligands are developed and available for human studies, it will be necessary to know which neuroreceptor measures result in increased neuronal activity and how regional activation relates to behavior. Thus, while new ligands and improved resolution are welcome and exciting, as is development of methods for fMRI, finding the neural basis of schizophrenia will require more than applying "the right method." Rather, it seems that we will have to undertake the challenging route of focused hypothesisdriven translational research where functional imaging provides the bridge between basic brain processes and behavior, including cognition and emotion. This will enhance our ability to articulate a neuropsychiatric perspective of schizophrenia. Within this framework, laterality provides a hypothesis that seems to be sustained when examined rigorously. Its specific shape and its distribution along other brain dimensions such as corticalsubcortical and anterior-posterior remain to be systematically elucidated.
